HCV Next Current Issue
The following articles appeared in the print edition of HCV Next.
Table of Contents
- The Evolution of Special Populations in HCV
-
- A Conversation with Hetal A. Karsan, MD
- The Disappearance of 'Special' Populations
- Guidance on When and in Whom to Initiate HCV Therapy
- A Look at Drug Cost, Financial Assistance Opportunities Leah Molloy, PharmD
- ARFI Accurately Detected Liver Fibrosis Stage in Patients with HCV
- Half of Patients with HIV Not Screened Regularly for HCV
- High sCD 163 Levels Predicted Fibrosis in Patients with HCV, HBV
- Hispanic Veterans with HCV at Increased Risk for Cirrhosis, HCC
-
- Patients with Chronic HCV at Increased Risk for Low Muscle Mass
- Study Finds Rising Incidence of HCV in Young, Non-Urban Injection Drug Users
- HCV, Alcohol-Use Disorder Heightens Risk for Liver-Related Mortality
- Minimal Severe, Serious Adverse Events Reported with '3D' HCV Regimen
- Bridging the Gap: New Clinical Trials Planned for Children with HCV Yen Pham, MD; Philip J. Rosenthal, MD
- Discontinuation of Telaprevir Expected in October
- European Commission Approves Daclatasvir Across Multiple Genotypes
- Societies Provide Tools to Meet New Competency Requirements
-
- World Hepatitis Alliance Launches HCV Quest